Page 16 - Read Online

Hidalgo M, Erkan M, Kleeff J, Scarpa A, Sainz B Jr, Heeschen C. DE, Chung CH, Lu B. Targeting the mechanisms of resistance
Intracellular autofluorescence: a biomarker for epithelial cancer to chemotherapy and radiotherapy with the cancer stem cell
stem cells. Nat Methods 2014;11:1161-9. hypothesis. J Oncol 2011;2011:941876.
24. Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R, Li J, Zhang Y, 41. Vaz AP, Ponnusamy MP, Batra SK. Cancer stem cells and therapeutic
Chen L, Qian H, Wu M, Yin Z. Sphere-forming cell subpopulations targets: an emerging field for cancer treatment. Drug Deliv Transl
with cancer stem cell properties in human hepatoma cell lines. BMC Res 2013;3:113-20.
Gastroenterol 2011;11:71. 42. Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, Lu
25. Wang K, Wu X, Wang J, Huang J. Cancer stem cell theory: QS, Singh S, Yang DH, Talele TT, Ambudkar SV, Chen ZS. The
therapeutic implications for nanomedicine. Int J Nanomedicine phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of
2013;8:899-908. ABCB1/P-glycoprotein transporter. PLoS One 2011;6:e19329.
26. Smalley M, Piggott L, Clarkson R. Breast cancer stem cells: 43. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau
obstacles to therapy. Cancer Lett 2013;338:57-62. MD, Gottesman MM, Varticovski L, Ambudkar SV. Prolonged drug
27. Suman S, Das TP, Damodaran C. Silencing NOTCH signaling selection of breast cancer cells and enrichment of cancer stem cell
causes growth arrest in both breast cancer stem cells and breast characteristics. J Natl Cancer Inst 2010;102:1637-52.
cancer cells. Br J Cancer 2013;109:2587-96. 44. Dönmez Y, Gündüz U. Reversal of multidrug resistance by small
28. Zang S, Chen F, Dai J, Guo D, Tse W, Qu X, Ma D, Ji C. RNAi- interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast
mediated knockdown of Notch-1 leads to cell growth inhibition cancer cells. Biomed Pharmacother 2011;65:85-9.
and enhanced chemosensitivity in human breast cancer. Oncol Rep 45. Li X, Li P, Zhang Y, Zhou Y, Chen X, Huang Y, Liu Y. Novel
2010;23893-9. Mixed Polymeric Micelles for Enhancing Delivery of Anticancer
29. Gupta S, Takebe N, Lorusso P. Targeting the Hedgehog pathway in Drug and Overcoming Multidrug Resistance in Tumor Cell Lines
cancer. Ther Adv Med Oncol 2010;2:237-50. Simultaneously. Pharm Res 2010;27:1498-511.
30. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, 46. Šubr V, Koziolová E, Sivák L, Říhová B, Kovář M, Ulbrich K.
Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, Polymer inhibitors of ABC transporter overcoming multidrug
VanArsdale T, Beachy PA, Reya T. Hedgehog signalling is essential resistance: Synthesis, characterization and in vitro evaluation. J
for maintenance of cancer stem cells in myeloid leukaemia. Nature Control Release 2015;213:e107-8.
2009;458:776-9. 47. Falasca M, Linton KJ. Investigaional ABC transporter inhibitors.
31. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart Expert Opin Investig Drugs 2012;21:657-66.
CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, 48. Schatton T, Frank MH. Antitumor immunity and cancer stem cells.
Beachy PA. Medulloblastoma growth inhibition by hedgehog Ann N Y Acad Sci 2009;1176:154-69.
pathway blockade. Science 2002;297:1559-61. 49. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson
32. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM.
Lauwers GY, Qi YP, Gysin S, Fernández-del Castillo C, Yajnik V, Characterization of circulating T cells specific for tumor-associated
Antoniu B, McMahon M, Warshaw AL, Hebrok M. Hedgehog is an antigens in melanoma patients. Nat Med 1999;5:677-85.
early and late mediator of pancreatic cancer tumorigenesis. Nature 50. Khong HT, Wang QJ, Rosenberg SA. Identification of multiple
2003;425:851-6. antigens recognized by tumor-infiltrating lymphocytes from a single
33. Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST. patient: tumor escape by antigen loss and loss of MHC expression. J
Deletion of the WNT target and cancer stem cell marker CD44 in Immunother 2004;27:184-90.
Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 51. Ames E, Canter RJ, Grossenbacher SK, Mac S, Chen M, Smith RC,
2008;68:3655-61. Hagino T, Perez-Cunningham J, Sckisel GD, Urayama S, Monjazeb
34. Hallett RM, Kondratyev MK, Giacomelli AO, Nixon AM, Girgis- AM, Fragoso RC, Sayers TJ, Murphy WJ. NK Cells Preferentially
Gabardo A, Ilieva D, Hassell JA. Small molecule antagonists of Target Tumor Cells with a Cancer Stem Cell Phenotype. J Immunol
the Wnt/β-catenin signaling pathway target breast tumor-initiating 2015;195:4010-9.
cells in a Her2/Neu mouse model of breast cancer. PLoS One 52. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases
2012;7:e33976. CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood
35. Gu W, Yeo E, McMillan N, Yu C. Silencing oncogene expression 2006;107:2409-14.
in cervical cancer stem-like cells inhibits their cell growth and self- 53. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber
renewal ability. Cancer Gene Ther 2011;18:897-905. JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of
36. Puca F, Colamaio M, Federico A, Gemei M, Tosti N, Bastos AU, 283 consecutive patients with metastatic melanoma or renal cell
Del Vecchio L, Pece S, Battista S, Fusco A. HMGA1 silencing cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-13.
restores normal stem cell characteristics in colon cancer stem cells 54. Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL.
by increasing p53 levels. Oncotarget 2014;5:3234-45. Regression of established pulmonary metastases and subcutaneous
37. Wang T, Gantier MP, Xiang D, Bean AG, Bruce M, Zhou SF, tumor mediated by the systemic administration of high-dose
Khasraw M, Ward A, Wang L, Wei MQ, AlShamaileh H, Chen L, She recombinant interleukin 2. J Exp Med 1985;161:1169-88.
X, Lin J, Kong L, Shigdar S, Duan W. EpCAM aptamer-mediated 55. Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific
survivin silencing sensitized cancer stem cells to doxorubicin in a cytotoxic T lymphocytes in the infiltrate of human metastatic
breast cancer model. Theranostics 2015;5:1456-72. melanomas. Activation by interleukin 2 and autologous tumor cells,
38. Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting and involvement of the T cell receptor. J Exp Med 1988;168:1419-41.
cancer stem cells: a new paradigm in immunotherapy? MAbs 56. Powell DJ Jr, de Vries CR, Allen T, Ahmadzadeh M, Rosenberg SA.
2009;1:12-25. Inability to mediate prolonged reduction of regulatory T Cells after
39. Zinzi L, Contino M, Cantore M, Capparelli E, Leopoldo M, transfer of autologous CD25-depleted PBMC and interleukin-2 after
Colabufo NA. ABC transporters in CSCs membranes as a novel lymphodepleting chemotherapy. J Immunother 2007;30:438-47.
target for treating tumor relapse. Front Pharmacol 2014;5:163. 57. Canter RJ, Grossenbacher SK, Ames E, Murphy WJ. Immune
40. Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt targeting of cancer stem cells in gastrointestinal oncology. J
240
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ July 8, 2016 ¦